SPORE in Lung Cancer

肺癌中的孢子

• 批准号: 8118138
• 负责人: ERIC B. HAURA
• 金额: $ 190万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8118138
• 关键词: SPORE; Lung; Cancer

The 5-year survival from lung cancer has kept pace with the improvement in 5-year survival from all cancers over the last 40 years. Yet, it remains disappointingly low at ~15%. This improvement in 5-year survival is a result of heightened awareness, better technology for detection, better selection of patients for various therapeutic options, and the selective use of palliative interventions. However, lung cancer mortality remains extraordinarily high, and it is the benchmark by which future generations will judge our success in effectively combating this disease. The Moffitt Cancer Center SPORE in Lung Cancer will 1) elucidate mechanisms of action of crucial molecules in lung carcinogenesis and tumor progression and investigate their impact on therapeutic efficacy and 2) prospectively assess the clinical utility of the molecules for therapeutic and prevention interventions. Our ultimate goal is to change the standard of care for people at risk for and with lung cancer. The SPORE has five translational research projects, three cores, a developmental research program, and a career development program. The projects are: 1) E2Fs Impact on Therapeutic Efficacy (Cress, Chen & Bepler) 2) RRM1 in the Management of Lung Cancer (Bepler, Cress & Simon) 3) Antitumor Mechanisms of Src Inhibitors in Lung Cancer (Haura, Cheng & Pledger) 4) Lung Cancer Chemoprevention with Enzastaurin (Bepler & Alexandrow) 5) p53-Based Vaccine for Small Cell Lung Cancer (Gabrilovich & Antonia) They are support by: A) Tissue Procurement, Pathology, and Bioinformatics Core (Altiok & Fenstermacher) B) Clinical Trials & Biostatistics Core (Simon, Schell & Bepler) C) Administration & Patient Advocacy Core (Bepler, Cress & Quinn). The SPORE also has Developmental Research & Career Development Programs. This SPORE will be firmly integrated into the H. Lee Moffitt Cancer Center and Research Institute, a free-standing, NCI designated Comprehensive Cancer in Tampa, Florida.

肺癌的5年生存与过去40年中所有癌症的5年生存率的改善保持同步。然而，它仍然令人失望地低约15％。 5年生存的这种改善是提高认识，更好的检测技术，更好地选择各种治疗选择的患者以及选择性使用姑息干预措施的结果。但是，肺癌的死亡率仍然很高，这是我们子孙后代在有效地打击这种疾病方面取得成功的基准。肺癌中的莫菲特癌中心孢子将1）阐明至关重要的分子在肺癌发生和肿瘤进展中的作用机制，并研究它们对治疗功效的影响，2）前瞻性评估分子对治疗和预防干预措施的临床实用性。我们的最终目标是改变患有肺癌和患有肺癌风险的人的护理标准。孢子有五个转化研究项目，三个核心，一个发展研究计划和一个职业发展计划。 项目是： 1）E2F对治疗功效的影响（Cress，Chen和Bepler） 2）RRM1在肺癌管理中（Bepler，Cress＆Simon） 3）肺癌中SRC抑制剂的抗肿瘤机制（Haura，Cheng＆Pledger） 4）肺癌化学预防与Enzastaurin（Bepler＆Alexandrow） 5）基于P53的小细胞肺癌疫苗（Gabrilovich＆Antonia） 他们得到支持： A）组织采购，病理学和生物信息学核心（Altiok＆Fenstermacher） b）临床试验与生物统计学核心（Simon，Schell＆Bepler） c）管理和患者倡导核心（Bepler，Cress＆Quinn）。 孢子还具有发展研究和职业发展计划。该孢子将牢固地整合到H. Lee Moffitt癌症中心和研究所，该研究所是佛罗里达州坦帕市自制的NCI综合癌症。